Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9998532 | 1.00 | MAPT (0.48) | MAPTPTGS1AKR1C2PTGS2FBP1 | |
| SCHEMBL9997776 | 0.89 | MAPT (0.46) | MAPTPTGS1AKR1C2PTGS2FBP1 | |
| SCHEMBL9997774 | 0.89 | MAPT (0.46) | MAPTPTGS1AKR1C2PTGS2FBP1 | |
| SCHEMBL9997905 | 0.84 | LMNA (0.41) | MAPTPTGS1PTGS2FBP1GLO1 | |
| SCHEMBL9997881 | 0.84 | LMNA (0.41) | MAPTPTGS1PTGS2FBP1GLO1 | |
| SCHEMBL9998417 | 0.84 | CNR2 (0.42) | MAPTPTGS1AKR1C2AKR1C3NFE2L2 | |
| SCHEMBL9998418 | 0.84 | CNR2 (0.42) | MAPTPTGS1AKR1C2AKR1C3NFE2L2 | |
| SCHEMBL9997580 | 0.84 | PTGS1 (0.47) | MAPTPTGS1AKR1C2PTGS2FBP1 | |
| SCHEMBL9997583 | 0.84 | PTGS1 (0.47) | MAPTPTGS1AKR1C2PTGS2FBP1 | |
| SCHEMBL9998522 | 0.83 | PTGS1 (0.43) | MAPTPTGS1AKR1C2PTGS2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8558012-B2 | 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative, production method thereof, and production method of monofluoromethyl group-containing compound using the same | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | CBR1, CYP1B1, CYP2F1 | MAPT 2206/4885PTGS1 683/4885AKR1C2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.